Aquestive Therapeutics
AQST
35 hedge funds and large institutions have $43.2M invested in Aquestive Therapeutics in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.86% less ownership
Funds ownership: 58.11% → 54.25% (-3.9%)
13% less funds holding
Funds holding: 40 → 35 (-5)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
29% less capital invested
Capital invested by funds: $61M → $43.2M (-$17.8M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$334K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$182K |
| 3 |
Two Sigma Investments
New York
|
+$156K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$111K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.48M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$673K |
| 3 |
Millennium Management
New York
|
-$622K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$314K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$213K |
AQST Hedge Fund Activity: Q3 2019 in Review
35 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2019, worth a combined $43.2M — down 29% from $61M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of AQST and 8 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was JP Morgan Chase, adding an estimated $334K. The largest seller was Opaleye Management, exiting entirely with an estimated $2.48M sold.
- 35 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2019, down from 40 in Q2 2019.
- Funds reported $43.2M of Aquestive Therapeutics stock for Q3 2019, down 29% quarter-over-quarter.
- 8 funds opened new Aquestive Therapeutics positions in Q3 2019 and 13 closed out, a net change of -5 holders.
- The largest Aquestive Therapeutics buyer in Q3 2019 was JP Morgan Chase, an estimated $334K added.
- The largest Aquestive Therapeutics seller in Q3 2019 was Opaleye Management, an estimated $2.48M sold.
Based on aggregated 13F filings for Q3 2019.